Table 3. Antienteroviral Activities against Four CVB Subtypes of Representative Compounds.
|
17b |
24d |
28e |
RBV |
|||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| compd | TC50 (μM)a | IC50 (μM)b | SIc | TC50 (μM)a | IC50 (μM)b | SIc | TC50 (μM)a | IC50 (μM)b | SIc | TC50 (μM)a | IC50 (μM)b | SIc |
| CVB1 | 489.8 | 2.60 | 188.4 | 169.8 | 1.46 | 116.0 | 183.3 | 1.28 | 143.5 | 8196 | 1951 | 4.2 |
| CVB2 | 489.8 | 12.6 | 38.9 | 169.8 | 1.44 | 117.2 | 127.1 | 7.61 | 16.7 | 8196 | 2101 | 3.9 |
| CVB5 | 489.8 | 10.5 | 46.7 | 169.8 | 3.63 | 46.8 | 73.4 | 8196 | 910.8 | 9.0 | ||
| CVB6 | 489.8 | 2.81 | 174.3 | 169.8 | 0.62 | 275.5 | 61.1 | 0.44 | 139.4 | 8196 | 1708 | 4.8 |
a
Cytotoxic concentration required to inhibit Vero cell growth by 50%.
b
Concentration required to inhibit CVB growth by 50%.
c
Selectivity index: TC50/IC50.